Picture BIO Deutschland Corona Special Germany 2020 650x80px
Person › Details

Johannes Baillou (E. Merck KG)

Baillou, Johannes (Merck (DE) 201401– Chairman of Board of Partners E Merck KG)


Products Product CHEMICALS
  Product 2 pharmaceutical

Merck KGaA. (1/28/14). "Press Release: New Appointments to Supervisory Bodies of E. Merck. Frank Stangenberg-Haverkamp and Johannes Baillou Become Most Senior Representatives". Darmstadt.

> Jon Baumhauer retires for age reasons

E. Merck KG, which combines the financial interests of the Merck family and is general partner of Merck with an interest of 70%, announced today that at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG.

Dr. Frank Stangenberg-Haverkamp (65) has been elected as the new Chairman of the twelve-member Family Board. Jon Baumhauer (69), previously Chairman of the Family Board and Chairman of the Executive Board of E. Merck KG, has retired from his offices for age reasons.

"For decades, Jon Baumhauer has uniquely shaped and successfully led the company and the Merck family of owners. The partners are exceptionally grateful to him for his leadership of the community of family members and for familiarizing the next generation with the company," said Stangenberg-Haverkamp, praising the achievements of his predecessor.

Baumhauer was elected to the Board of Partners of Merck in 1979. In 1989 he became Vice Chairman of this body and from 1994 to 2004 he served as Chairman of the Board of Partners. In 2004, he took over the chairmanship of the Family Board.

The Family Board newly appointed the nine members of the Board of Partners of E. Merck KG. The Board of Partners is comparable to the supervisory board of a German stock corporation (AG). It supervises the executive management of Merck KGaA and is responsible for the appointment Executive Board members of Merck KGaA.

Johannes Baillou (48) has been elected Chairman of the Board of Partners. He has been a member of the Board of Partners since 2009 and served as Vice Chairman of this body since then. Stangenberg-Haverkamp, who has been a member of the Board of Partners since 1984, has been elected Vice Chairman. In addition, Dr. Wolfgang Büchele (54), Dr. Siegfried Karjetta (59), Albrecht Merck (64), Prof. Dr. Helga Rübsamen-Schaeff (65), Prof. Dr. Gregor Schulz (63), Prof. Dr. Theo Siegert (66), and Tobias Thelen (37) have been elected to the Board of Partners.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website Please go to to register online, change your selection or discontinue this service.

Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Record changed: 2020-03-28


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Johannes Baillou

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top